All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Novartis receives FDA approval for Rhapsido, first oral BTK inhibitor for chronic spontaneous urticaria
Small molecule, autoimmune, BTK inhibitor, chronic spontaneous urticaria, oral therapy - Read more

THE GOOD
Business Development & Partnerships

Kyorin, Hinge Bio license preclinical lupus drug HB2198 for Japan, $105M total deal
Licensing deal, autoimmune, antibody, milestone payments - Read more

Astex, Bristol Myers Squibb, Takeda join AbbVie, Johnson & Johnson in AI drug discovery data pooling initiative
Research collaboration, AI/ML, drug discovery, small molecule - Read more

JCR Pharmaceuticals, Menagen license Fabry disease therapy across nine MENAT markets
Licensing deal, rare disease, enzyme replacement therapy, MENAT region, commercialization - Read more

PRESENTED BY YOU?
Get the attention of 2200+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

✅ More Good News ✅

THE GOOD
Clinical Trials

Vertanical's VER-01 cannabis extract outperforms opioids in Ph3 chronic low back pain studies
Plant extract, pain management, cannabis extract, chronic low back pain, opioid alternative - Read more

Cellphire's CLPH-511 frozen platelets meet primary endpoint in Ph2/3 trial for acute hemorrhage treatment
Cell therapy, hemorrhage, platelet therapy, acute hemorrhage, cardiopulmonary bypass surgery, trauma - Read more

THE GOOD
Fundraises

Aerska raises $21M seed funding for RNA drugs targeting brain diseases
Neurological, RNA interference, brain delivery, Alzheimer disease, Parkinson disease, platform technology - Read more

Toragen raises $12M convertible note, HPV cancer treatment development
Oncology, small molecule, clinical-stage, HPV-driven cancers - Read more

Athernal Bio raises £3.5M ($4.71M) funding, developing immunotherapies for blood cancer precursors
Oncology, immunotherapy, blood cancer, preclinical - Read more

Ansa raises $54.4M Series B to scale enzymatic DNA synthesis platform
DNA synthesis, platform technology, synthetic biology, gene therapy - Read more

Appili Therapeutics awarded $40M NIAID contract, developing VXV-01 fungal vaccine
Infectious disease, vaccine development, antifungal, clinical-stage - Read more

SeaBeLife raises $2.25M pre-Series A, developing necrosis-blocking drugs for AMD/hepatitis
Small molecule, ophthalmology, hepatitis, necroptosis inhibitor, preclinical - Read more

Enanta Pharmaceuticals raises $65M public offering, clinical-stage virology and immunology drugs
Clinical-stage, small molecule, virology, immunology - Read more

THE GOOD
Investments

AbbVie launches $70M Massachusetts bioresearch center expansion under $10B US investment strategy
Biologics, oncology, strategic, major transaction, operational - Read more

THE GOOD
Mergers & Acquisitions

Halozyme acquires Elektrofi for $900M to expand subcutaneous drug delivery technology portfolio
Drug delivery technology, strategic, major transaction, operational - Read more

THE GOOD
Politics & Policy

Trump doubles pediatric cancer data initiative funding to $100M amid broader biomedical research cuts
Artificial intelligence, pediatric oncology, strategic, major transaction, regulatory - Read more

Trump delays 100% pharma tariffs to negotiate pricing concessions and manufacturing investment deals with industry
Pharmaceutical manufacturing, regulatory, strategic, major transaction - Read more

THE GOOD
Product Launches

Chugai launches PiaSky in Taiwan as first approved subcutaneous treatment for paroxysmal nocturnal hemoglobinuria
Monoclonal antibody, rare disease, regulatory, strategic - Read more

THE GOOD
Strategic Plans

AnaptysBio plans business split into separate biopharma operations and royalty management entities by 2026
Monoclonal antibody, autoimmune, strategic, major transaction, financial - Read more

THE BAD
Approvals & Labels

FDA issues complete response letter for Cyprium/Sentynl's CUTX-101 copper histidinate for menkes disease over manufacturing issue
Protein therapy, neurological, copper histidinate, Menkes disease, rare pediatric disease, manufacturing issues - Read more

THE BAD
Lawsuits

Indivior halts Opvee promotion, settles with New York over alleged deceptive marketing to public officials
Small molecule, addiction/overdose, legal settlement, operational, reputational - Read more

THE BAD
Layoffs

Takeda exits cell therapy, cuts 137 Massachusetts jobs, seeks partner for platform worth $394M
Cell therapy, oncology, strategic, cost reduction, operational - Read more

THE UGLY
Politics & Policy

NIH halts all basic research and grant payments as government shutdown furloughs 75% of staff
Regulatory, operational, financial, strategic - Read more

THE UGLY
Regulatory

EU raids Sanofi's France, Germany offices over alleged flu vaccine market abuse concerns
Vaccine, infectious disease, regulatory, competitive, operational - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here